Skip to content

Comparison of sumatriptan and propofol VS Sumatriptan and placebo in acute migraine

Comparison of sumatriptan and propofol VS Sumatriptan and placebo in acute migraine

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015050422089N1
Enrollment
60
Registered
2016-01-29
Start date
2014-09-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine without aura (common migraine )

Interventions

Intervention 1: In intervention group after starting IV Line 30 microgram/kg/ Propofol in 100cc normal saline infused for one hour and 6 miligram Sumatriptane injected subcutaneously . Intervention
Treatment - Drugs
In intervention group after starting IV Line 30 microgram/kg/ Propofol in 100cc normal saline infused for one hour and 6 miligram Sumatriptane injected subcutaneously .
In control group after starting IV line100 cc normal saline as placebo infused for one hour and 6 miligram Sumatriptane injected subcutaneousely.

Sponsors

Vice chancellor for research, Shahid Sadoughi university of Medical Science Of Yazd
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: all patient aged 18 to 45 years old with migrain headache Exclusion criteria: Pregnancy, Hypertension, Previous CVA, propofol sensitivity, Sumatriptan sensitivity, coronary artery disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: Before intervention, 10-minute iterval after intervention until 1 hour. Method of measurement: Visual pain score.

Secondary

MeasureTime frame
Hypoxia. Timepoint: Before intervention, 10- minute interval after intervention until 1 hour. Method of measurement: Pulse oximetry.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Marzieh Ghilian

Shahid Sadoughi University of Medical Science

marziehghilian@yahoo.com / ghilian@ssu.ac.ir+98 358223511

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026